Exelixis Inc Payments to Acquire Investments
Exelixis Inc (EXEL) reported Payments to Acquire Investments of $247.15 million for the 6-month period ending 2024-06-28, per its 10-Q filed 2024-08-06.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2024-08-06
- Exelixis Inc payments to acquire investments for the quarter ending 2024-06-28 was $108.69M, a 67.01% decline year-over-year.
- Exelixis Inc payments to acquire investments for the quarter ending 2024-03-29 was $138.47M, a 55.60% decline year-over-year.
- Exelixis Inc payments to acquire investments for the quarter ending 2023-12-29 was $78.62M, a 78.83% decline year-over-year.
- Exelixis Inc payments to acquire investments for the quarter ending 2023-09-29 was $182.52M, a 52.88% decline year-over-year.
- Exelixis Inc payments to acquire investments for fiscal 2023 was $902.47M, a 37.79% decline from fiscal 2022.
- Exelixis Inc payments to acquire investments for fiscal 2022 was $1.45B, a 6.89% increase from fiscal 2021.
- Exelixis Inc payments to acquire investments for fiscal 2021 was $1.36B, a 26.81% increase from fiscal 2021.
- Exelixis Inc payments to acquire investments for fiscal 2021 was $1.07B, a 9.50% decline from fiscal 2020.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2024-06-28 | $108.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $247.15M 10-Q · filed 2024-08-06 | $325.77M derived: sum of 3 quarters · filed 2024-08-06 | $508.29M derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-29 | $138.47M 10-Q · filed 2024-04-30 | $217.09M derived: sum of 2 quarters · filed 2024-04-30 | $399.61M derived: sum of 3 quarters · filed 2024-04-30 | $729.10M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-12-29 | $78.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-06 | $261.14M derived: sum of 2 quarters · filed 2024-02-06 | $590.63M derived: sum of 3 quarters · filed 2024-08-06 | $902.47M 10-K · filed 2024-02-06 |
| 2023-09-29 | $182.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $512.01M derived: sum of 2 quarters · filed 2024-08-06 | $823.85M 10-Q · filed 2023-11-01 | $1.20B derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-06-30 | $329.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $641.33M 10-Q · filed 2024-08-06 | $1.01B derived: sum of 3 quarters · filed 2024-08-06 | $1.40B derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $311.84M 10-Q · filed 2024-04-30 | $683.14M derived: sum of 2 quarters · filed 2024-04-30 | $1.07B derived: sum of 3 quarters · filed 2024-04-30 | $1.43B derived: sum of 4 quarters · filed 2024-04-30 |
| 2022-12-30 | $371.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-06 | $758.63M derived: sum of 2 quarters · filed 2024-02-06 | $1.11B derived: sum of 3 quarters · filed 2024-02-06 | $1.45B 10-K · filed 2024-02-06 |
| 2022-09-30 | $387.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $742.87M derived: sum of 2 quarters · filed 2023-11-01 | $1.08B 10-Q · filed 2023-11-01 | $1.36B derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-07-01 | $355.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $692.09M 10-Q · filed 2023-08-01 | $971.88M derived: sum of 3 quarters · filed 2024-02-06 | $1.36B derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-04-01 | $336.55M 10-Q · filed 2023-05-09 | $616.34M derived: sum of 2 quarters · filed 2024-02-06 | $1.00B derived: sum of 3 quarters · filed 2024-02-06 | $1.36B derived: sum of 4 quarters · filed 2024-02-06 |
| 2021-12-31 | $279.79M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-06 | $668.26M derived: sum of 2 quarters · filed 2024-02-06 | $1.03B derived: sum of 3 quarters · filed 2024-02-06 | $1.36B 10-K · filed 2024-02-06 |
| 2021-10-01 | $388.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $745.76M derived: sum of 2 quarters · filed 2022-11-01 | $1.08B 10-Q · filed 2022-11-01 | $1.28B derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-07-02 | $357.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $688.90M 10-Q · filed 2022-08-09 | $892.20M derived: sum of 3 quarters · filed 2023-02-07 | $1.33B derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-04-02 | $331.61M 10-Q · filed 2022-05-10 | $534.91M derived: sum of 2 quarters · filed 2023-02-07 | $968.73M derived: sum of 3 quarters · filed 2023-02-07 | $1.15B derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-01-01 | $203.29M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $637.12M derived: sum of 2 quarters · filed 2023-02-07 | $818.76M derived: sum of 3 quarters · filed 2023-02-07 | $1.07B 10-K · filed 2023-02-07 |
| 2020-10-02 | $433.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $615.47M derived: sum of 2 quarters · filed 2021-11-02 | $866.98M 10-Q · filed 2021-11-02 | $1.16B derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-07-03 | $181.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $433.15M 10-Q · filed 2021-08-05 | $728.14M derived: sum of 3 quarters · filed 2022-02-18 | $1.10B derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-04-03 | $251.50M 10-Q · filed 2021-05-06 | $546.49M derived: sum of 2 quarters · filed 2022-02-18 | $915.92M derived: sum of 3 quarters · filed 2022-02-18 | $1.19B derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-01-03 | $294.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $664.41M derived: sum of 2 quarters · filed 2022-02-18 | $942.81M derived: sum of 3 quarters · filed 2022-02-18 | $1.18B 10-K · filed 2022-02-18 |
| 2019-09-27 | $369.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $647.83M derived: sum of 2 quarters · filed 2020-11-05 | $887.70M 10-Q · filed 2020-11-05 | |
| 2019-06-28 | $278.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $518.27M 10-Q · filed 2020-08-06 | ||
| 2019-03-29 | $239.87M 10-Q · filed 2020-05-05 | |||
| 2018-12-28 | $557.83M 10-K · filed 2021-02-11 | |||
| 2017-12-29 | $319.09M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |